Momenta Pharmaceuticals Company Profile (NASDAQ:MNTA)

About Momenta Pharmaceuticals (NASDAQ:MNTA)

Momenta Pharmaceuticals logoMomenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection). GLATOPA 20 milligrams (mg)/ milliliters (mL) is a generic version of once-daily COPAXONE 20 mg/mL indicated for the treatment of patients with relapsing forms of multiple sclerosis, a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. COPAXONE is available in both a once-daily 20 mg/mL formulation and a three-times-weekly 40 mg/mL formulation. The Company's Enoxaparin Sodium Injection is a generic version of LOVENOX indicated for the prevention and treatment of deep vein thrombosis and to support the treatment of acute coronary syndromes. The Company's programs include M254, M281 (Anti-FcRn candidate) and M230.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:MNTA
  • CUSIP: 60877T10
  • Web:
  • Market Cap: $1.2354 billion
  • Outstanding Shares: 76,231,000
Average Prices:
  • 50 Day Moving Avg: $16.43
  • 200 Day Moving Avg: $15.55
  • 52 Week Range: $10.75 - $19.90
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -36.52
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $113.52 million
  • Price / Sales: 11.28
  • Book Value: $5.22 per share
  • Price / Book: 3.22
  • EBIDTA: ($83,150,000.00)
  • Net Margins: -39.35%
  • Return on Equity: -12.28%
  • Return on Assets: -9.18%
  • Current Ratio: 4.08%
  • Quick Ratio: 4.08%
  • Average Volume: 576,358 shs.
  • Beta: 1.82
  • Short Ratio: 9.13

Frequently Asked Questions for Momenta Pharmaceuticals (NASDAQ:MNTA)

What is Momenta Pharmaceuticals' stock symbol?

Momenta Pharmaceuticals trades on the NASDAQ under the ticker symbol "MNTA."

How were Momenta Pharmaceuticals' earnings last quarter?

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) issued its quarterly earnings results on Wednesday, August, 2nd. The company reported ($0.50) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.50). The business had revenue of $23.57 million for the quarter, compared to analysts' expectations of $24.64 million. Momenta Pharmaceuticals had a negative net margin of 39.35% and a negative return on equity of 12.28%. The company's revenue was down 10.8% compared to the same quarter last year. During the same quarter last year, the company posted ($0.31) EPS. View Momenta Pharmaceuticals' Earnings History.

When will Momenta Pharmaceuticals make its next earnings announcement?

Momenta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, October, 31st 2017. View Earnings Estimates for Momenta Pharmaceuticals.

Where is Momenta Pharmaceuticals' stock going? Where will Momenta Pharmaceuticals' stock price be in 2017?

7 brokers have issued twelve-month target prices for Momenta Pharmaceuticals' shares. Their predictions range from $6.00 to $26.00. On average, they expect Momenta Pharmaceuticals' share price to reach $16.71 in the next twelve months. View Analyst Ratings for Momenta Pharmaceuticals.

What are analysts saying about Momenta Pharmaceuticals stock?

Here are some recent quotes from research analysts about Momenta Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Momenta’s loss per share came in line with estimates in the second quarter of 2017 while sales beat estimates. The ANDA approval for Glatopa is contingent on the satisfactory resolution of the compliance observations stated in the warning letter issued by the FDA, resulting in a delay of approval. The warning letter will remain a major over hang on the shares till the issue is solved. Additionally, Glatopa faces competition from Teva’s thrice-weekly Copaxone. Moreover, the company's patents covering Enoxaparin Sodium Injection were declared invalid and unenforceable. Shares of the company have underperformed the industry so far in 2017. Nevertheless, sales of Glatopa 20mg continue to do well and have captured approximately 40% of the market in the U.S. In addition, a potential approval of M923 will boost investor confidence." (8/4/2017)
  • 2. Cowen and Company analysts commented, "Glatopa sales were $23M primarily, above our estimate of $20M driven by quarterly." (5/3/2017)
  • 3. Aegis analysts commented, "Warning letter delivered from FDA to fill/finish manufacturer. On Friday after market close, Momenta announced that Pfizer, Sandoz's contracted manufacturer for Glatopa, had received an FDA warning letter. While the facility is a key portion of Momenta's supply chain for Glatopa 20mg, the warning letter is not expected to restrict production or shipments. Since the Pfizer facility is where the final Glatopa 40 mg product will be manufactured, FDA policy states that compliance observations must be satisfactorily resolved before the ANDA can move forward. We anticipate this will translate into a 6-month delay for Glatopa 40 mg." (2/21/2017)
  • 4. Maxim Group analysts commented, "The District Court of Delaware ruled to invalidate several of Teva’s (TEVA- $33.43-Hold) patents protecting 40mg (3x weekly) Copaxone; Patents ‘250, ‘413, ‘302, and ‘776. In 2016, the Patent Trial and Appeal Board (PTAB) declared these patents invalid due to obviousness through an inter partes review (IPR) proceeding." (2/1/2017)

Who are some of Momenta Pharmaceuticals' key competitors?

Who are Momenta Pharmaceuticals' key executives?

Momenta Pharmaceuticals' management team includes the folowing people:

  • Craig A. Wheeler, President, Chief Executive Officer, Director
  • Ganesh Venkataraman Kaundinya Ph.D., Co-Founder, Senior Vice President - Research, Chief Scientific Officer
  • Scott M. Storer, Chief Financial Officer, Senior Vice President
  • Bruce A. Leicher, Senior Vice President, General Counsel, Secretary
  • Bruce L. Downey, Independent Director
  • Corey N. Fishman, Independent Director
  • Georges Gemayel Ph.D., Independent Director
  • Steven C. Gilman Ph.D., Independent Director
  • Jose-Carlos Gutierrez-Ramos Ph.D., Independent Director

Who owns Momenta Pharmaceuticals stock?

Momenta Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (15.16%), BlackRock Inc. (12.81%), Vanguard Group Inc. (8.51%), State Street Corp (3.48%), Palo Alto Investors LLC (2.34%) and Fiera Capital Corp (2.27%). Company insiders that own Momenta Pharmaceuticals stock include Bruce Leicher, Craig A Wheeler, Ganesh Venkataraman Kaundinya, James M Roach, John E Bishop, Michael Franken and Richard P Shea. View Institutional Ownership Trends for Momenta Pharmaceuticals.

Who sold Momenta Pharmaceuticals stock? Who is selling Momenta Pharmaceuticals stock?

Momenta Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Discovery Capital Management LLC CT, Numeric Investors LLC, Tekla Capital Management LLC, Fiera Capital Corp, Sectoral Asset Management Inc, Russell Investments Group Ltd., First Trust Advisors LP and Voya Investment Management LLC. Company insiders that have sold Momenta Pharmaceuticals stock in the last year include Bruce Leicher, Craig A Wheeler, Ganesh Venkataraman Kaundinya, James M Roach and Richard P Shea. View Insider Buying and Selling for Momenta Pharmaceuticals.

Who bought Momenta Pharmaceuticals stock? Who is buying Momenta Pharmaceuticals stock?

Momenta Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Acadian Asset Management LLC, Renaissance Technologies LLC, FMR LLC, Ameriprise Financial Inc., Vanguard Group Inc., TIAA CREF Investment Management LLC and State Street Corp. View Insider Buying and Selling for Momenta Pharmaceuticals.

How do I buy Momenta Pharmaceuticals stock?

Shares of Momenta Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Momenta Pharmaceuticals' stock price today?

One share of Momenta Pharmaceuticals stock can currently be purchased for approximately $16.80.

MarketBeat Community Rating for Momenta Pharmaceuticals (NASDAQ MNTA)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  250 (Vote Outperform)
Underperform Votes:  209 (Vote Underperform)
Total Votes:  459
MarketBeat's community ratings are surveys of what our community members think about Momenta Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Momenta Pharmaceuticals (NASDAQ:MNTA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 4 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.14)
Consensus Price Target: $16.71 (0.51% downside)

Analysts' Ratings History for Momenta Pharmaceuticals (NASDAQ:MNTA)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/3/2017Maxim GroupSet Price TargetSell$6.00LowView Rating Details
8/3/2017Stifel NicolausReiterated RatingBuy$26.00LowView Rating Details
5/22/2017Barclays PLCDowngradeOverweight -> Equal Weight$20.00 -> $17.00HighView Rating Details
5/3/2017Cowen and CompanyReiterated RatingHold$15.00LowView Rating Details
5/3/2017AegisReiterated RatingHold$17.00LowView Rating Details
2/21/2017Leerink SwannDowngradeOutperform -> Market Perform$18.00 -> $18.00N/AView Rating Details
11/3/2016J P Morgan Chase & CoReiterated RatingBuy$18.00N/AView Rating Details
8/5/2016Brean CapitalSet Price TargetBuy$19.00N/AView Rating Details
6/6/2016Goldman Sachs Group, Inc. (The)Initiated CoverageNeutral$14.00N/AView Rating Details
(Data available from 9/21/2015 forward)


Earnings History for Momenta Pharmaceuticals (NASDAQ:MNTA)
Earnings by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)
Earnings History by Quarter for Momenta Pharmaceuticals (NASDAQ MNTA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/31/2017($0.47)N/AView Earnings Details
8/2/2017Q2 2017($0.50)($0.50)$24.64 million$23.57 millionViewListenView Earnings Details
5/2/2017Q1 2017($1.09)($0.46)$21.29 million$26.61 millionViewListenView Earnings Details
2/21/2017Q416($0.24)$0.60$29.56 million$34.20 millionViewListenView Earnings Details
11/2/2016Q316($0.29)($0.26)$25.68 million$299.14 millionViewN/AView Earnings Details
8/4/2016Q216($0.34)($0.31)$23.55 million$26.40 millionViewN/AView Earnings Details
5/3/2016Q116($0.32)($0.35)$28.12 million$19.90 millionViewN/AView Earnings Details
2/18/2016Q415($0.04)($0.43)$30.42 million$22.40 millionViewListenView Earnings Details
11/4/2015Q315($0.19)($0.44)$31.76 million$13.80 millionViewListenView Earnings Details
8/4/2015Q215($0.39)($0.04)$23.59 million$44.90 millionViewListenView Earnings Details
5/1/2015Q115($0.48)($0.40)$11.70 million$8.60 millionViewN/AView Earnings Details
2/17/2015Q414($0.16)($0.31)$23.80 million$21.18 millionViewListenView Earnings Details
11/5/2014Q314($0.43)($0.56)$13.00 million$9.34 millionViewListenView Earnings Details
7/31/2014Q214($0.49)($0.51)$11.22 million$11.00 millionViewListenView Earnings Details
5/6/2014Q1($0.55)($0.53)$8.41 million$10.79 millionViewListenView Earnings Details
2/10/2014Q4($0.45)($0.59)$8.50 million$12.80 millionViewListenView Earnings Details
11/5/2013Q313($0.48)($0.50)$8.60 million$10.80 millionViewN/AView Earnings Details
8/1/2013Q2 2013($0.45)($0.57)$8.85 million$4.40 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.44)($0.48)$10.28 million$7.60 millionViewN/AView Earnings Details
2/15/2013Q4 2012($0.41)($0.35)$10.41 million$12.70 millionViewN/AView Earnings Details
11/7/2012Q312($0.27)($0.51)$16.48 million$5.10 millionViewN/AView Earnings Details
8/2/2012($0.17)($0.20)ViewN/AView Earnings Details
5/3/2012$0.02($0.10)ViewN/AView Earnings Details
2/9/2012$0.13($0.02)ViewN/AView Earnings Details
11/7/2011$1.28$1.18ViewN/AView Earnings Details
8/4/2011$1.21$1.26ViewN/AView Earnings Details
5/5/2011$0.95$1.13ViewN/AView Earnings Details
2/10/2011$0.81$0.77ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Momenta Pharmaceuticals (NASDAQ:MNTA)
2017 EPS Consensus Estimate: ($0.58)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.36)($0.36)($0.36)
Q2 20171($0.30)($0.30)($0.30)
Q3 20171($0.20)($0.20)($0.20)
Q4 20171$0.28$0.28$0.28
(Data provided by Zacks Investment Research)


Dividend History for Momenta Pharmaceuticals (NASDAQ:MNTA)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Momenta Pharmaceuticals (NASDAQ:MNTA)
Insider Ownership Percentage: 4.40%
Institutional Ownership Percentage: 93.86%
Insider Trades by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)
Institutional Ownership by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)
Insider Trades by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/1/2017Craig A. WheelerPresidentSell20,367$17.00$346,239.00View SEC Filing  
8/21/2017Bruce LeicherSVPSell802$15.20$12,190.40View SEC Filing  
8/21/2017Craig A WheelerPresidentSell4,116$15.07$62,028.12View SEC Filing  
8/21/2017Ganesh Venkataraman KaundinyaVPSell821$15.20$12,479.20View SEC Filing  
8/10/2017Bruce LeicherSVPSell350$16.60$5,810.00View SEC Filing  
8/10/2017Craig A. WheelerPresidentSell16,953$16.94$287,183.82View SEC Filing  
8/10/2017Ganesh Venkataraman KaundinyaVPSell387$16.60$6,424.20View SEC Filing  
8/2/2017Craig A WheelerPresidentSell200$17.00$3,400.00View SEC Filing  
5/22/2017Bruce LeicherSVPSell859$14.80$12,713.20View SEC Filing  
5/19/2017Craig A WheelerPresidentSell4,116$15.83$65,156.28View SEC Filing  
5/19/2017Ganesh Venkataraman KaundinyaVPSell821$15.90$13,053.90View SEC Filing  
5/10/2017Bruce LeicherSVPSell347$16.00$5,552.00View SEC Filing  
5/10/2017Craig A. WheelerPresidentSell1,852$15.77$29,206.04View SEC Filing  
5/10/2017Ganesh Venkataraman KaundinyaVPSell384$16.00$6,144.00View SEC Filing  
12/15/2016Richard P SheaCFOSell9,799$15.00$146,985.00View SEC Filing  
12/9/2016Richard P SheaCFOSell1,451$15.00$21,765.00View SEC Filing  
11/22/2016Bruce LeicherSVPSell1,030$13.66$14,069.80View SEC Filing  
11/22/2016Craig A. WheelerPresidentSell5,880$13.68$80,438.40View SEC Filing  
11/22/2016James M RoachVPSell1,091$13.67$14,913.97View SEC Filing  
11/22/2016Richard P SheaCFOSell971$13.67$13,273.57View SEC Filing  
8/22/2016Bruce LeicherSVPSell1,030$12.05$12,411.50View SEC Filing  
8/22/2016Craig A. WheelerPresidentSell5,880$12.02$70,677.60View SEC Filing  
8/22/2016James M RoachVPSell1,091$12.05$13,146.55View SEC Filing  
8/22/2016Richard P SheaCFOSell972$12.05$11,712.60View SEC Filing  
5/20/2016Bruce LeicherSVPSell1,000$10.40$10,400.00View SEC Filing  
5/20/2016Craig A WheelerPresidentSell5,880$10.18$59,858.40View SEC Filing  
5/20/2016Ganesh Venkataraman KaundinyaVPSell1,050$10.18$10,689.00View SEC Filing  
5/20/2016Richard P SheaCFOSell973$10.18$9,905.14View SEC Filing  
5/19/2016John E BishopVPSell784$10.20$7,996.80View SEC Filing  
4/19/2016John E BishopVPSell2,843$9.57$27,207.51View SEC Filing  
2/23/2016John E BishopVPSell329$9.70$3,191.30View SEC Filing  
2/22/2016Bruce LeicherSVPSell227$9.65$2,190.55View SEC Filing  
2/22/2016Craig A WheelerPresidentSell1,688$9.95$16,795.60View SEC Filing  
2/22/2016John E BishopVPSell2,848$9.66$27,511.68View SEC Filing  
2/19/2016Bruce LeicherSVPSell2,000$9.64$19,280.00View SEC Filing  
2/19/2016Craig A WheelerPresidentSell9,844$9.37$92,238.28View SEC Filing  
2/19/2016John E. BishopVPSell357$10.28$3,669.96View SEC Filing  
2/19/2016Richard P SheaCFOSell1,823$9.64$17,573.72View SEC Filing  
2/18/2016Bruce LeicherSVPSell337$10.49$3,535.13View SEC Filing  
2/18/2016James M RoachVPSell272$10.49$2,853.28View SEC Filing  
2/18/2016Richard P SheaCFOSell183$10.49$1,919.67View SEC Filing  
2/17/2016Craig A WheelerPresidentSell1,688$11.30$19,074.40View SEC Filing  
12/11/2015Michael FrankenInsiderSell520$15.84$8,236.80View SEC Filing  
11/20/2015Craig A WheelerPresidentSell1,766$17.86$31,540.76View SEC Filing  
11/19/2015Craig A WheelerPresidentSell2,061$18.05$37,201.05View SEC Filing  
11/17/2015Craig A WheelerPresidentSell1,766$17.70$31,258.20View SEC Filing  
11/5/2015Craig A. WheelerPresidentSell51,667$18.00$930,006.00View SEC Filing  
8/20/2015Craig A WheelerPresidentSell1,766$22.28$39,346.48View SEC Filing  
8/19/2015Craig A WheelerPresidentSell2,061$22.02$45,383.22View SEC Filing  
8/19/2015James M. RoachVPSell7,011$22.09$154,872.99View SEC Filing  
8/18/2015James M RoachVPSell6,812$21.80$148,501.60View SEC Filing  
8/17/2015Craig A WheelerPresidentSell1,766$21.77$38,445.82View SEC Filing  
7/15/2015Elizabeth StonerDirectorSell4,570$22.35$102,139.50View SEC Filing  
6/19/2015John E BishopVPSell21,274$25.50$542,487.00View SEC Filing  
6/18/2015Bruce LeicherSVPSell20,000$23.00$460,000.00View SEC Filing  
6/18/2015Craig A WheelerPresidentSell155,000$24.20$3,751,000.00View SEC Filing  
6/18/2015John E BishopVPSell36,313$23.58$856,260.54View SEC Filing  
6/4/2015Craig A WheelerPresidentSell103,333$22.00$2,273,326.00View SEC Filing  
6/1/2015Bruce LeicherSVPSell40,000$21.00$840,000.00View SEC Filing  
6/1/2015James M RoachVPSell25,000$21.70$542,500.00View SEC Filing  
5/20/2015Craig A WheelerPresidentSell1,766$19.68$34,754.88View SEC Filing  
5/19/2015Craig A WheelerPresidentSell2,061$19.67$40,539.87View SEC Filing  
4/23/2015Craig A WheelerPresidentSell51,667$20.00$1,033,340.00View SEC Filing  
4/23/2015Ganesh Venkataraman KaundinyaVPSell34,000$19.95$678,300.00View SEC Filing  
4/20/2015Craig A WheelerPresidentSell6,269$18.75$117,543.75View SEC Filing  
4/17/2015Bruce LeicherSVPSell52,910$19.52$1,032,803.20View SEC Filing  
4/16/2015James M RoachVPSell50,000$18.70$935,000.00View SEC Filing  
3/16/2015Richard P SheaCFOSell23,093$15.10$348,704.30View SEC Filing  
3/5/2015Richard P SheaCFOSell23,364$14.90$348,123.60View SEC Filing  
2/24/2015Craig A WheelerPresidentSell2,110$13.52$28,527.20View SEC Filing  
2/20/2015Bruce LeicherSVPSell1,891$12.97$24,526.27View SEC Filing  
2/20/2015Craig A WheelerPresidentSell9,563$13.49$129,004.87View SEC Filing  
2/20/2015John E BishopVPSell1,768$12.97$22,930.96View SEC Filing  
2/20/2015Richard P SheaCFOSell1,812$12.97$23,501.64View SEC Filing  
2/18/2015Craig A WheelerPresidentSell1,688$11.91$20,104.08View SEC Filing  
12/15/2014Bennett M ShapiroDirectorSell5,800$12.19$70,702.00View SEC Filing  
12/11/2014Michael FrankenInsiderSell2,047$12.29$25,157.63View SEC Filing  
12/1/2014Bennett M ShapiroDirectorSell9,903$12.00$118,836.00View SEC Filing  
11/28/2014Bennett M ShapiroDirectorSell1,897$12.00$22,764.00View SEC Filing  
11/25/2014Craig A WheelerPresidentSell2,210$11.59$25,613.90View SEC Filing  
11/20/2014Craig A WheelerPresidentSell1,768$11.10$19,624.80View SEC Filing  
11/17/2014Craig A WheelerPresidentSell1,768$10.58$18,705.44View SEC Filing  
10/3/2014Bennett M ShapiroDirectorSell3,723$12.00$44,676.00View SEC Filing  
9/12/2014Peter Barton HuttDirectorSell3,640$11.42$41,568.80View SEC Filing  
8/25/2014Craig A WheelerPresidentSell2,209$11.45$25,293.05View SEC Filing  
8/20/2014Craig A WheelerPresidentSell1,768$11.54$20,402.72View SEC Filing  
8/15/2014Bennett M ShapiroDirectorSell3,722$12.00$44,664.00View SEC Filing  
8/15/2014Craig A WheelerPresidentSell1,768$11.75$20,774.00View SEC Filing  
8/13/2014Bennett M ShapiroDirectorSell3,721$12.00$44,652.00View SEC Filing  
5/23/2014Craig A WheelerPresidentSell2,110$12.06$25,446.60View SEC Filing  
5/20/2014Craig WheelerPresidentSell1,688$12.08$20,391.04View SEC Filing  
5/15/2014Craig WheelerPresidentSell1,687$11.09$18,708.83View SEC Filing  
2/25/2014Craig WheelerPresidentSell2,109$17.47$36,844.23View SEC Filing  
2/24/2014John BishopVPSell1,038$17.67$18,341.46View SEC Filing  
2/19/2014Craig WheelerPresidentSell3,797$17.90$67,966.30View SEC Filing  
2/12/2014Ganesh Venkataraman KaundinyaVPSell33,000$17.96$592,680.00View SEC Filing  
1/9/2014John BishopVPSell27,159$19.50$529,600.50View SEC Filing  
11/25/2013Bruce LeicherSVPSell13,492$18.00$242,856.00View SEC Filing  
11/25/2013Craig WheelerPresidentSell2,215$17.77$39,360.55View SEC Filing  
11/25/2013Ganesh Venkataraman KaundinyaVPSell33,211$18.02$598,462.22View SEC Filing  
11/19/2013Craig WheelerPresidentSell2,215$17.17$38,031.55View SEC Filing  
11/15/2013Craig WheelerPresidentSell1,772$16.88$29,911.36View SEC Filing  
10/11/2013John BishopVPSell5,247$15.46$81,118.62View SEC Filing  
8/23/2013Craig WheelerPresidentSell2,109$14.90$31,424.10View SEC Filing  
8/20/2013Craig WheelerPresidentSell2,109$14.47$30,517.23View SEC Filing  
8/15/2013Craig WheelerPresidentSell1,688$15.43$26,045.84View SEC Filing  
7/26/2013Richard P SheaCFOSell30,000$16.61$498,300.00View SEC Filing  
6/27/2013Richard P SheaCFOSell10,522$14.61$153,726.42View SEC Filing  
6/19/2013Richard P SheaCFOSell21,550$14.61$314,845.50View SEC Filing  
5/23/2013Craig A WheelerPresidentSell2,109$13.03$27,480.27View SEC Filing  
5/21/2013Craig A WheelerPresidentSell2,109$12.83$27,058.47View SEC Filing  
5/15/2013Craig A WheelerPresidentSell1,687$13.33$22,487.71View SEC Filing  
3/5/2013Elizabeth StonerDirectorSell2,040$14.00$28,560.00View SEC Filing  
2/15/2013Bruce LeicherSVPSell1,040$12.26$12,750.40View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Momenta Pharmaceuticals (NASDAQ:MNTA)
Latest Headlines for Momenta Pharmaceuticals (NASDAQ:MNTA)
DateHeadline logoMomenta (MNTA) Up 5.8% Since Earnings Report: Can It Continue? - September 7 at 5:58 AM logoMomenta Pharmaceuticals, Inc. (MNTA) President Craig A. Wheeler Sells 20,367 Shares - September 5 at 4:26 PM logoMomenta Pharmaceuticals, Inc. (MNTA) Receives Average Recommendation of "Hold" from Brokerages - September 5 at 10:44 AM logoMomenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : MNTA-US : September 1, 2017 - September 2 at 6:22 AM logoMomenta Pharmaceuticals to Webcast Presentation at the 2017 Wells Fargo Healthcare Conference - August 31 at 7:25 AM logoBruce Leicher Sells 802 Shares of Momenta Pharmaceuticals, Inc. (MNTA) Stock - August 23 at 8:50 PM logoGanesh Venkataraman Kaundinya Sells 821 Shares of Momenta Pharmaceuticals, Inc. (MNTA) Stock - August 23 at 8:50 PM logoCraig A. Wheeler Sells 4,116 Shares of Momenta Pharmaceuticals, Inc. (MNTA) Stock - August 23 at 8:28 PM logoMomenta Pharmaceuticals, Inc. (MNTA) Cut to Sell at BidaskClub - August 22 at 6:22 PM logoMomenta Pharmaceuticals, Inc. (MNTA) President Craig A. Wheeler Sells 16,953 Shares - August 14 at 4:30 PM logoSee what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc. - August 12 at 7:54 PM logoMomenta Pharmaceuticals, Inc. – Value Analysis (NASDAQ:MNTA) : August 12, 2017 - August 12 at 5:41 AM logoMomenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Receives Average Rating of "Hold" from Brokerages - August 11 at 6:19 PM logoIHS Markit Score downgrades Momenta Pharmaceuticals Inc to 30 out of 100, ranking positively in only one out of three available IHS Markit categories. - August 11 at 6:38 AM logoIHS Markit Score downgrades Momenta Pharmaceuticals Inc to 30 out of 100, ranking positively in only one out of three available IHS Markit categories. - August 11 at 6:38 AM logoMomenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : MNTA-US : August 10, 2017 - August 11 at 6:38 AM logoMomenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : MNTA-US : August 10, 2017 - August 11 at 6:38 AM logoMomenta Pharmaceuticals, Inc. (MNTA) Lowered to "Sell" at Zacks Investment Research - August 6 at 5:14 PM logoMomenta Pharmaceuticals, Inc. Treads Water in the Second Quarter - August 3 at 4:12 PM logoMomenta Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update - August 3 at 5:47 AM logoEdited Transcript of MNTA earnings conference call or presentation 2-Aug-17 2:00pm GMT - August 3 at 5:47 AM logoMomenta reports 2Q loss - August 3 at 5:47 AM logoMomenta Pharmaceuticals, Inc. (MNTA) Posts Earnings Results, Hits Expectations - August 2 at 3:04 PM logoMomenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : MNTA-US : July 28, 2017 - July 28 at 4:25 PM logoMomenta Phama (MNTA) is 'Disappointed' by Jury Verdict in Enoxaparin Sodium Injection Patent Litigation - July 22 at 6:35 AM logoMomenta Pharmaceuticals Announces Date of Second Quarter 2017 Financial Results Conference Call and Webcast - July 20 at 1:26 AM logoMomenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Given Average Recommendation of "Hold" by Analysts - July 17 at 11:34 AM logoETFs with exposure to Momenta Pharmaceuticals, Inc. : July 10, 2017 - July 11 at 2:14 AM logoMomenta Pharmaceuticals, Inc. (MNTA) Downgraded by BidaskClub to "Hold" - July 6 at 9:04 PM logoMomenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Downgraded by Zacks Investment Research - July 4 at 1:41 PM logoETFs with exposure to Momenta Pharmaceuticals, Inc. : June 27, 2017 - June 27 at 6:44 PM logoMomenta Pharmaceuticals, Inc. (MNTA) Upgraded to "Buy" at BidaskClub - June 23 at 7:38 PM logoMomenta Pharmaceuticals, Inc. (MNTA) Receives Consensus Recommendation of "Hold" from Analysts - June 20 at 10:46 AM logoInvestors Purchase High Volume of Momenta Pharmaceuticals Put Options (MNTA) - June 16 at 8:25 AM logoMylan In FDA Limbo On Generic Multiple Sclerosis Drug - June 16 at 7:49 AM logoImplied Volatility Surging for Momenta Pharmaceuticals (MNTA) Stock Options - June 13 at 6:44 PM logoETFs with exposure to Momenta Pharmaceuticals, Inc. : June 12, 2017 - June 12 at 3:58 PM logoMomenta Pharmaceuticals, Inc. :MNTA-US: Earnings Analysis: Q1, 2017 By the Numbers : June 9, 2017 - June 9 at 6:47 PM logoMomenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 38th Annual Global Healthcare Conference - June 7 at 9:05 AM logoWhy Is Momenta Pharmaceuticals (MNTA) Down 9.7% Since the Last Earnings Report? - June 5 at 9:17 AM logoMomenta Phama (MNTA) Appoints Santiago Arroyo as CMO - June 1 at 7:25 PM logoMomenta Pharmaceuticals Appoints Santiago Arroyo, M.D., Ph.D. as Chief Medical Officer - June 1 at 9:21 AM logoNovartis warns of U.S. price pressure on Sandoz generics - May 31 at 7:58 AM logoMomenta Pharmaceuticals, Inc. (MNTA) Receives Consensus Rating of "Hold" from Analysts - May 26 at 10:50 AM logoInsider Selling: Momenta Pharmaceuticals, Inc. (MNTA) VP Sells 821 Shares of Stock - May 23 at 4:46 PM logoMomenta Pharmaceuticals, Inc. (MNTA) SVP Bruce Leicher Sells 859 Shares - May 23 at 4:46 PM logoInsider Selling: Momenta Pharmaceuticals, Inc. (MNTA) President Sells 4,116 Shares of Stock - May 23 at 4:34 PM logoMomenta Pharmaceuticals, Inc. (MNTA) Stock Rating Lowered by Barclays PLC - May 22 at 4:29 PM logoMomenta Pharmaceuticals, Inc. (MNTA) President Craig A. Wheeler Sells 1,852 Shares - May 12 at 4:26 PM logoUPDATE -- Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences - May 10 at 6:40 PM



Momenta Pharmaceuticals (MNTA) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by Staff